549 related articles for article (PubMed ID: 25965365)
1. Anti-PD-1 therapy in melanoma.
Homet Moreno B; Parisi G; Robert L; Ribas A
Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; MandalĂ M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
4. The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.
Tsai KK; Daud AI
Drugs; 2015 Apr; 75(6):563-75. PubMed ID: 25802230
[TBL] [Abstract][Full Text] [Related]
5. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
Eggermont AM; Maio M; Robert C
Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Chen DS; Irving BA; Hodi FS
Clin Cancer Res; 2012 Dec; 18(24):6580-7. PubMed ID: 23087408
[TBL] [Abstract][Full Text] [Related]
10. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
McDermott J; Jimeno A
Drugs Today (Barc); 2015 Jan; 51(1):7-20. PubMed ID: 25685857
[TBL] [Abstract][Full Text] [Related]
13. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab for the treatment of cancer.
Gunturi A; McDermott DF
Expert Opin Investig Drugs; 2015 Feb; 24(2):253-60. PubMed ID: 25494679
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Pal SK; Hu A; Chang M; Figlin RA
Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
Karim S; Leighl N
Future Oncol; 2016 Jan; 12(1):9-23. PubMed ID: 26631501
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint modulation for non-small cell lung cancer.
Soria JC; Marabelle A; Brahmer JR; Gettinger S
Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]